Merck drug less effective against moderate Covid - India regulatory source
Merck & Co's experimental antiviral drug molnupiravir has not shown "significant efficacy" against moderate Covid-19, a source with the Drug Controller General of India said.
Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate Covid-19 patients, the regulator's expert committee said on Friday...
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable